Phibro Animal Health Corporation filed a Form 8-K on November 4, 2026, disclosing voting results from its November 3, 2026 annual stockholder meeting and announcing the release of fiscal first-quarter operating results for the period ended September 30, 2026.

Key Highlights

  • Quorum reached: Holders of 18,569,002 Class A shares and 19,496,034 Class B shares were present, representing 98.8% of total voting power as of the September 11, 2026 record date.
  • Three directors elected: Daniel M. Bendheim, Jonathan Bendheim, and Sam Gejdenson were each elected as Class I Directors to serve until the 2029 annual meeting.
  • Gejdenson received fewest votes for: Sam Gejdenson received 204,161,701 votes for and 8,080,482 votes withheld, the highest withheld count among the three nominees.
  • PwC ratified: PricewaterhouseCoopers LLP was ratified as independent auditor for fiscal year ending June 30, 2027, with 212,226,587 votes for and 1,300,652 votes against.
  • Quarterly results announced: The company issued a press release on November 4, 2026 covering operating results for the fiscal quarter ended September 30, 2026 and financial guidance for the fiscal year ending June 30, 2027.

Annual Meeting Outcomes and Quarterly Disclosure at Phibro Animal Health

According to the filing, Phibro Animal Health Corporation (NASDAQ:PAHC) held its annual meeting of stockholders on November 3, 2026, in Teaneck, New Jersey. Stockholders voted on two proposals: the election of three Class I Directors and the ratification of the company's independent registered public accounting firm. Class A stockholders were entitled to one vote per share, while Class B stockholders were entitled to ten votes per share, with both classes voting together as a single class on all matters.

The filing reports that all three director nominees were duly elected. Daniel M. Bendheim received 208,245,393 votes for and 3,996,790 votes withheld. Jonathan Bendheim received 207,303,181 votes for and 4,939,002 votes withheld. Sam Gejdenson received 204,161,701 votes for and 8,080,482 votes withheld. Each nominee also had 1,287,159 broker non-votes. Each elected director will serve until the 2029 annual meeting and until his or her successor is duly elected and qualified, according to the filing.

On the auditor ratification proposal, the filing states that PricewaterhouseCoopers LLP received 212,226,587 votes for, 1,300,652 votes against, and 2,101 abstentions, with no broker non-votes recorded. Separately, the company disclosed that on November 4, 2026, it issued a press release announcing operating results for the fiscal quarter ended September 30, 2026, along with financial guidance for the fiscal year ending June 30, 2027. The press release was furnished as Exhibit 99.1 and is noted as not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

What Was Disclosed

Phibro Animal Health filed an 8-K on November 4, 2026, covering its November 3, 2026 annual stockholder meeting voting results, including director elections and auditor ratification, as well as furnishing a press release on first-quarter fiscal results and full-year guidance.